Long non-coding RNA GASL1 inhibits proliferation and invasion of osteosarcoma cells via modulation of the PI3K/Akt pathway

Feng Gao1, Feng Xu2

1Department of Orthopedics, The Second Hospital of Jilin University, Changchun, Jilin, China
2Department of Spinal Surgery, The First Bethune Hospital of Jilin University, Changchun, Jilin, China

Submitted: 16 June 2019; Accepted: 1 October 2019
Online publication: 11 November 2019
Arch Med Sci 2023; 19 (3): 717–723
DOI: https://doi.org/10.5114/aoms.2019.89662
Copyright © 2019 Termedia & Banach

Abstract

Introduction: Studies have shown long non-coding RNAs to be involved in a wide array of cancer-related processes. This study analyzed the role of LncRNA GAL1 in osteosarcoma cancer proliferation, migration and invasion of cancer cells.

Material and methods: The qRT-PCR technique was used to determine the expression of GASL1. MTT assay was performed for analysis of cell viability. Migration of cancer cells was monitored by wound healing assay. Transwell assay was used for analysis of cancer cell invasion. Western blotting was performed for determination of protein expression levels.

Results: The results showed that GASL1 exhibits lower expression in osteosarcoma tissues and cell lines than normal surroundings tissues and osteoblasts respectively. GASL1 overexpression resulted in a decline of cancer cell viability as revealed by MTT and colony formation assays. The migration and invasion of cancer cells decreased remarkably when GASL1 was overexpressed in cancer cells. GASL1 over-expression also affected the Bax/Bcl-2 ratio and promoted cell apoptosis. The anticancer effects of GASL1 overexpression were found to be mediated via the PI3K/Akt signaling pathway. GASL1 was seen to play an inhibitory role in PI3K and Akt phosphorylation.

Conclusions: Long ncRNA GASL1 inhibits the growth of osteosarcoma cancer cells. Cell apoptosis was promoted via inactivation of the PI3K/Akt signaling pathway. Taken together LncRNA GAL1 may prove to be a beneficial therapeutic target in the treatment of osteosarcoma.

Key words: GASL1, osteosarcoma, proliferation, apoptosis, migration, invasion.

Introduction

Osteosarcoma, which is represented by either the direct immature bone genesis or formation of osteoid tissue by tumor cells, is a primary malignant tumor of the skeleton [1]. It is considered as one of the rarest cancers with an incidence of only 4 cases per million annually. Osteosarcoma is more common among children and adolescents [2]. Cancer, in general, is a deviation from a normal cellular program which is associated with abnormalities at the transcriptional level. Therefore, the study of behavior of cancer-related transcripts can help in designing better diagnos-
otic strategies for early detection and prevention of cancer development. Transcriptome studies have revealed that transcription is a surprisingly complex process which results in the production of long non-coding RNA (ncRNA) transcripts which are often overlapping or interspaced between coding and non-coding transcripts [3, 4]. The transcript length of long ncRNA is generally > 200 nucleotides [5]. Long ncRNAs were previously considered as redundant by-products of RNA polymerase II transcription but many studies have revealed that they are involved in a number of regulatory processes including somatic tissue differentiation and tumor development [6–10]. Recently, many studies have focused on the role of long ncRNA in cancer development and metastasis [11, 12]. Our current work was designed to investigate the role of growth- associated long ncRNA 1 (GASL1). GASL1 has already been reported to inhibit the tumor growth in gastric sarcoma by blocking the Wnt/β-catenin signaling pathway [13]. In the present study, the role of GASL1 was explored in osteosarcoma cells along with the underlying mechanism of action. The quantitative reverse transcriptase real-time polymerase chain reaction (qRT-PCR) based expression analysis showed that cancer cells exhibit lower transcript abundance of GASL1. Overexpression of GASL1 long ncRNA resulted in a decline of cell viability and cancer cell migration and invasion. Cell apoptosis was promoted considerably in the GASL1 over-expressing cancer cells. The induction of cellular apoptotic cell death was mediated through modulation of the Bax/Bcl-2 pathway. Western blot analysis showed that the increased expression of GASL1 resulted in a decrease in abundance of phosphorylated PI3K and Akt which resulted in inactivation of the PI3K/ Akt signaling pathway and thus inhibition of cancer cell proliferation and metastasis. To sum up, the results of the current study indicate GASL1 to be an important negative regulator of osteosarcoma cell proliferation and metastasis. Thus, GASL1 downregulation may be used as a biomarker for osteosarcoma and may also prove to be a therapeutic target for the treatment of osteosarcoma.

**Material and methods**

**Culture, maintenance and transfection of cell lines**

Osteosarcoma cancer cell lines MG-63, HOS, 143B, T1-7 Saos-2 and the hFOB1.19 human osteoblastic cell line were procured from ATCC (Manassas, VA, USA). The cell lines were maintained as previously reported [14]. A humidified chamber was used for incubation of cell lines at 37°C with 5% CO2. Lipofectamine 2000 was used to transfect the cells either with control pcDNA3.1 or pcDNA-GASL1 construct for 48 h.

**RNA isolation, cDNA synthesis and quantitative RT-PCR**

The total RNA was extracted using the Pure-Link RNA Mini Kit according to the manufacturer’s protocol. DNA contamination was removed by DNase I treatment. cDNA was synthesized using High-Capacity cDNA Archive Kit. RT-PCR analysis was carried out using the SYBR Green method. The expression of GASL1 was inferred using the GASL1-F (CTAGGGCCA AAGTTCCAAC) and GASL1-R (CAGCCTGACCTTCCCT CTCC) primer pair. The amplification conditions were 95°C for 3 min, 40 cycles of 95°C for 15 s, 55°C for 15 s, 68°C for 15 s, followed by 95°C for 1 min, 55°C for 1 min and 70°C for 6 s. The human actin gene was used as an internal control for expression studies.

**Assessment of cell viability**

The 3-[4, 5-dimethylthiazolyl-2]-2, 5-diphenyltetrazolium bromide (MTT) reagent was used for determination of cancer cells. Briefly, after 0, 12, 24, 48, 96 h cell transfection with pcDNA3.1 and pcDNA-GASL1, the cells were seeded into a 96-well plate at a density of 1 × 10^4 cells/well and incubated with 0.5% MTT at 37°C for a period of 4 h. To solubilise MTT-formazan, 150 µl of DMSO was added to each well. The absorbance at 570 nm was recorded.

**Colony formation assay**

The cells were grown in 6-well plates for 12 h until the density reached 1 × 10^3 /100 µl of medium. This was followed by 48 h incubation at 37°C with 5% CO2 concentration. The cell pellet was harvested by centrifugation and washed with PBS buffer. Each cell pellet was resuspended in 1 ml of 0.1% crystal violet solution and incubated for 30 min. The cells were again collected by centrifugation and washed with PBS buffer until the suspension became clear. Then, the colonies were counted and pictures were taken.

**AO/EB staining for assessment of cell death**

The acridine orange/ethidium bromide (AO/EB) staining method was used to estimate the apoptotic cell death. In brief, Saos-2 and MG-63 cells transfected with pcDNA3.1 and pcDNA-GASL1 were plated in 96-well plates at a density of 2 × 10^3 cells/well. An aliquot of 25 µl from each well was mixed with 1 µl of dye phosphate buffered saline solution containing 100 µg of each acridine orange and ethidium bromide (both supplied by Sigma Chemical Company). About 10 µl of this mix was put on a glass slide, covered with a cover
The overexpression of GASL1 in Saos-2 and MG-63 cancer cell lines was achieved by using the pcDNA3.1 vector via the transfection method. The stable transformation of GASL1 was confirmed by nearly 6-7 fold enhanced expression of the former in cancer cells in comparison to pcDNA3.1 vector transfected (NC) cells (Figure 1 B). To assess the viability of NC and GASL1 overexpressing cancer cells, cells were transfected and processed for MTT assay at 0, 12, 24, 48 and 96 h of transfection. The absorbance was taken at 570 nm, which is indicative of viability of cells, and it was seen that NC cells had higher O.D. in comparison to GASL1 overexpressing Saos-2 and MG-63 cells and the difference was more notable at longer durations of transfection (Figure 1 C). This suggests that cancer cell viability decreases with increase in GASL1 expression. This was also confirmed by remarkably low clone forming ability of GASL1 overexpressing cancer cells (Figure 2).

Statistical analysis

For each experiment, at least three independent replicates were performed. The final values are presented as mean ± standard deviation. Student’s t-test was performed using GraphPad Prism 7 software to compare the values. P < 0.05 was indicative of a statistically significant difference.

Results

GASL1 is downregulated in osteosarcoma

Expression analysis of lncRNA GASL1 by qRT-PCR in normal osteoblast cells and osteosarcoma cell lines showed that GASL1 exhibits significantly lower expression in cancer cells (Figure 1 A). This reveals that osteosarcoma proceeds with lowering of GASL1 expression.

Overexpression of GASL1 inhibits osteosarcoma cell proliferation

The overexpression of GASL1 in Saos-2 and MG-63 cancer cell lines was achieved by using the pcDNA3.1 vector via the transfection method. The stable transformation of GASL1 was confirmed by nearly 6-7 fold enhanced expression of the former in cancer cells in comparison to pcDNA3.1 vector transfected (NC) cells (Figure 1 B). To assess the viability of NC and GASL1 overexpressing cancer cells, cells were transfected and processed for MTT assay at 0, 12, 24, 48 and 96 h of transfection. The absorbance was taken at 570 nm, which is indicative of viability of cells, and it was seen that NC cells had higher O.D. in comparison to GASL1 overexpressing Saos-2 and MG-63 cells and the difference was more notable at longer durations of transfection (Figure 1 C). This suggests that cancer cell viability decreases with increase in GASL1 expression. This was also confirmed by remarkably low clone forming ability of GASL1 overexpressing cancer cells (Figure 2).

Elevation of GASL1 expression leads to Bax/Bcl-2 mediated cell apoptosis

The acridine orange/ethidium bromide (AO/EB) staining method was employed for analysis of cell apoptosis in cancer cells. The fluorescence microscopic investigation of NC and Saos-2 and MG-63 cell lines overexpressing GASL1 showed deformation of chromatin material (Figure 3 A). To check whether overexpression of GASL1 in cancer cells modulated the Bax/Bcl-2 apoptotic signal, western blotting was performed. The expression of Bax protein was elevated while Bcl-2 expression was downregulated (Figure 3 B).

GASL1 overexpression inhibits migration and invasion of osteosarcoma cells

Cell migration and invasion are crucial to metastasis. Wound healing and transwell experiments were performed for assessment of migration and invasion of osteosarcoma cells. The results showed that cell migration was inhibited dramatically in GASL1 overexpressing cancer cells (Figure 4). GASL1 overexpression also resulted in a decline in the invasion of osteosarcoma cells. The percentage of invasion decreased to only 45% and 57% in GASL1 overexpressing Saos-2 and MG-63 cells, respectively, in comparison to respective NC cells (Figure 5).
Overexpression of GASL1 inactivates PI3K/Akt signaling pathway

Finally, to analyze the underlying molecular mechanism of inhibition of cancer proliferation under GASL1 overexpression, western blotting of PI3K, phosphorylated PI3K (p-PI3K), Akt and phosphorylated Akt (p-Akt) was performed. The protein expression showed that GASL1 overexpression hardly had any effect on PI3K and Akt protein levels but there was a surprising decrease in p-PI3K and p-Akt protein concentrations (Figure 6). This is suggestive of inactivation of PI3K/Akt signaling upon overexpression of GASL1 in osteosarcoma cells. The effects of PI3K/Akt signal modulation are evident as reduction of cancer cell proliferation and metastasis.

Discussion

Osteosarcoma is one of the rarest malignant tumors. Of the all biopsy-analyzed malignant bone tumors, it has a frequency of only about 15% [1]. A number of studies have proven long ncRNA as an important regulators of cancer development but there is hardly any such report for osteosarcoma. GASL1 ncRNA has already been shown to inhibit cell proliferation by inducing cell apoptosis. The down-regulation of GASL1 resulted in cell cycle progression via the promotion of G1 exit in cancer cells [16].
Long non-coding RNA GASL1 inhibits proliferation and invasion of osteosarcoma cells via modulation of the PI3K/Akt pathway

Figure 2. Colony formation assay of Saos-2 and MG-63 transfected with NC and pcDNA-GASL1. The experiments were performed in triplicate and expressed as mean ± SD (*p < 0.05)

Figure 3. A – AO/EB staining showing the induction of apoptosis in Saos-2 and MG-63 cells transfected with NC or pcDNA-GASL1. B – Western blots showing the expression of Bax and Bcl-2 in NC and pcDNA-GASL1 transfected Saos-2 and MG-63 cells. The experiments were performed in triplicate and expressed as mean ± SD (*p < 0.05)
It also inhibited the progression of lung cancer by blocking the TGF-β signaling pathway [17]. A recent study showed that GASL1 has an inhibitory role in prostate carcinoma [18]. In order to unravel the role of GASL1 in osteosarcoma, expression analysis was carried out in infected bone tissue and non-infected surrounding tissue and it was observed that GASL1 has significantly lower expression in the infected tissue, suggesting its probable regulatory role in osteosarcoma. This was also evident from higher expression of GASL1 in human osteoblast cells in comparison to osteosarcoma cancer cell lines. Analysis of cell viability showed that overexpression of GASL1 resulted in loss of cell proliferation and promoted the apoptosis of cancer cells. The reduction in cell proliferation of cancer cells was mediated via blockage of the PI3K/Akt signaling pathway. The western blotting analysis showed that GASL1 exerts its negative regulatory effect by inhibiting the phosphorylation of PI3K and Akt. This in turn inhibits the
Long non-coding RNA GASL1 inhibits proliferation and invasion of osteosarcoma cells via modulation of the PI3K/Akt pathway

**Figure 6.** Effect of lncRNA GASL1 overexpression on the PI3K/AKT signaling pathway. The experiments were performed in triplicate.

expression of downstream genes important for cell proliferation and cancer metastasis. When GASL1 was overexpressed in osteosarcoma cancer cells, their ability to migrate and invade was reduced to a considerable level. This indicates that metastasis of osteosarcoma progresses with the expression of GASL1, progression of osteosarcoma is halted. Further, inactivation of PI3K/Akt pathway induced cell apoptosis has already been established by Chao et al. in 2010 [19] and our results also suggest the same. GASL1 induced apoptosis is also clear from protein expression of Bax and Bcl-2 apoptosis related protein. Bax was seen to be overexpressed while Bcl-2 protein concentration was reduced considerably. Taken together, the results indicate that GASL1 acts as a negative regulator in osteosarcoma cancer progression. Its anticancer role is evidenced as its ability to inhibit the proliferation and metastasis of osteosarcoma cells via modulation of the PI3K/Akt signaling pathway and to promote cell apoptosis by modulating the Bax/Bcl-2 ratio.

In conclusion, osteosarcoma at the molecular level proceeds with downregulation of long ncRNA GASL1. The overexpression GASL1 in cancer cells inhibited cell proliferation, migration and invasion by inactivating PI3K/Akt signaling. The study may pave the way for utilization of LncRNA GASL1 for the treatment of osteosarcoma.

**Conflict of interest**

The authors declare no conflict of interest.

**References**

1. Picci P. Osteosarcoma (osteogenic sarcoma). Orphanet J Rare Dis 2007; 2: 6.
2. Ottaviani G, Jaffe N. The epidemiology of osteosarcoma. In: Pediatric and Adolescent Osteosarcoma. Springer, Boston, MA 2009; 3-13.
3. Carninci P, Kasukawa T, Katayama S, et al. The transcriptional landscape of the mammalian genome. Science 2005; 309: 1559-63.
4. Karpanov P, Drenkow J, Cheng J, et al. Examples of the complex architecture of the human transcriptome revealed by RACE and high-density tiling arrays. Genome Res 2005; 15: 987-97.
5. Ponting CR, Oliver PL, Reik W. Evolution and functions of long noncoding RNAs. Cell 2009; 136: 629-41.
6. Mercer TR, Dinger ME, Mattick JS. Long non-coding RNAs: Insights into functions. Nat Rev Genet 2009; 10: 155-9.
7. Wilusz JE, Sunwoo H, Spector DL. Long non-coding RNAs: functional surprises from the RNA world. Genes Dev 2009; 23: 1494-504.
8. Geisler S, Coller J. RNA in unexpected places: long non-coding RNA functions in diverse cellular contexts. Nat Rev Mol Cell Biol 2013; 14: 699-712.
9. Kretz M, Siprashvili Z, Chu C, et al. Control of somatic tissue differentiation by the long non-coding RNA TINCR. Nature 2013; 493: 231-5.
10. Gibb EA, Brown CJ, Lam WL. The functional role of long non-coding RNA in human carcinomas. Mol Cancer 2011; 10: 38.
11. Shi X, Sun M, Liu H, et al. A critical role for the long non-coding RNA GAS5 in proliferation and apoptosis in non-small-cell lung cancer. Mol Carcinog 2015; 54 (Suppl 1): E1-2.
12. Song Z, Xing F, Jiang H, He Y, Lv J. Long non-coding RNA TP73-AS1 predicts poor prognosis and regulates cell proliferation and migration in cervical cancer. Arch Med Sci 2022; 18: 523-34.
13. Peng C, Li X, Yu Y, Chen J. LncRNA GASL1 inhibits tumor growth in gastric carcinoma by inactivating the Wnt/ beta-catenin signaling pathway. Exp Therap Med 2019; 17: 4039-45.
14. Chen YQ, Yang TQ, Zhou B, Yang MX, Feng H, Wang YL. HOXAS overexpression promotes osteosarcoma cell apoptosis through the p53 and p38alpha MAPK pathway. Gene 2019; 689: 18-23.
15. Ma TT, Zhou LQ, Xiao JH, Shen Y, Yan Y, Zhu RH. LncRNA PCAT-1 regulates the proliferation, metastasis and invasion of cervical cancer cells. Eur Rev Med Pharmacol Sci 2018; 22: 1907-13.
16. Gasri-Plotnitsky L, Ovadia A, Shamaev K, et al. A novel LncRNA, GASL1, inhibits cell proliferation and restricts E2F1 activity. Oncotarget 2017; 8: 23775-86.
17. Su WZ, Yuan X. LncRNA GASL1 inhibits tumor growth of non-small cell lung cancer by inactivating TGF-beta pathway. Eur Rev Med Pharmacol Sci 2018; 22: 7282-8.
18. Li Z, Liu H, Ju W, Xing Y, Zhang X, Yang J. LncRNA GASL1 inhibits growth and promotes expression of apoptosis-associated proteins in prostate carcinoma cells through GLUT-1. Oncol Lett 2019; 17: 5327-34.
19. Chao X, Zao J, Xiao-Yi G, Li-Jun M, Tao S. Blocking of PI3K/AKT induces apoptosis by its effect on NF-kappaB activity in gastric carcinoma cell line SGC7901. Biomed Pharmacother 2010; 64: 600-4.